First Trust Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

First Trust Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,870	Closed	-$611K	–	2518
2021 Q1	$611K	Buy	3,870 +44	+1%	+$9.27K	﹤0.01%	2153
2020 Q4	$888K	Sell	3,826 -1,770	-32%	-$410K	﹤0.01%	1944
2020 Q3	$1.23M	Sell	5,596 -630	-10%	-$154K	﹤0.01%	1651
2020 Q2	$1.77M	Buy	+6,226	New	+$1.84M	﹤0.01%	1442
2019 Q2	–	Sell	-2,635	Closed	-$231K	–	2474
2019 Q1	$231K	Sell	2,635 -8,576	-76%	-$951K	﹤0.01%	2323
2018 Q4	$1.58M	Buy	+11,211	New	+$1.89M	﹤0.01%	1607

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

First Trust Advisors's KPTI Position: Q2 2021 in Review

First Trust Advisors sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 3,870 shares — an estimated $611K sold.

First Trust Advisors first reported a position in KPTI in Q4 2018 and held it in 6 quarters. The position peaked at $1.77M in Q2 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

First Trust Advisors reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
First Trust Advisors sold 3,870 Karyopharm Therapeutics shares in Q2 2021, an estimated $611K.
First Trust Advisors first reported a position in Karyopharm Therapeutics in Q4 2018 and held it in 6 quarters.
First Trust Advisors's Karyopharm Therapeutics position peaked at $1.77M in Q2 2020.
153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on First Trust Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.